Technology

In vivo AI CRO

C. elegans: Unique Model for High-Throughput Bio-Data Generation

Automated Preclinical CRO Platform Utilizing C. elegans
In vivo automated equipment
Microfluidic Kit for Multidimensional
Physiological Data Measurement
AI analytics SaaS
In vivo AI CRO

Bridging the Missing Link between Traditional CROs and AI-Driven Drug Discovery

Traditional CRO
Time to Completion
1Y
4.5Y
in vivo data
5,000
50
Microbiome

35.3% CAGR:
The Surging Microbiome Therapeutics Market

* Grand View Research

FDA-approved product
Rebyota, Vowst entering the market

bacterial/protein-based DDS
for stability & regulatory advantages

gut-brain immune axis
for CNS/inflammatory diseases
Microbiome

Microbiome Therapeutics Targeting Gut–Brain Axis

Microbiome

Gut-Brain Axis-Based Microbiome Engineering for Neurodegenerative Disorders and Parkinson’s Disease Inhibition

Indications
Platform Type
Development Stage
Parkinson’s, Alzheimer’s, Obesity
Spore-derived protein-based DDS + AI–C. elegans
Functional food launched, IND in preparation
Nanocomplex

The $17.7 Billion Global Nano-Cosmetics Opportunity

* The Business Resarch Company

The global nano-cosmetics market is surging toward a $17.7 billion (approx. 20 trillion KRW) valuation by 2029, reflecting a robust 16.2% CAGR.
Nanocomplex

Nano-Formulation of Proprietary Strains and Product Diversification

- Our proprietary platform engineers bio-macromolecules, including proteins, into high-performance nanomaterials optimized for both oral and topical delivery systems.

- This versatile technology enables a broad range of high-value applications, from neuro-supportive nutraceuticals targeting dopamine depletion to advanced therapeutic and cosmeceutical solutions for anti-aging and specialized skin-trouble care.
Nanocomplex

Precision Manufacturing of Oral Biologic Nanocarriers

* Biotechnology and Bioprocess Engineering 26: 40-50 (2021) DOI 10.1007/s12257-021-0243-6

Precision manufacturing of high-performance nanocarriers designed to prevent GI degradation and facilitate systemic absorption of biologics via the small intestine.
Nanocomplex

Targeted Oral Delivery & Systemic Absorption Mechanism

https://pubs.acs.org/doi/10.1021/acsami.3c11756
* ACS Applied Materials & Interfaces, 15, 44, 50889–50897 (2023).

Facilitates targeted release in the small intestine by bypassing gastric acidity. Prevents enzymatic breakdown to maximize systemic absorption of biologics, as validated through in vivo efficacy studies.

Get a 1:1 consultation with elegslab today.

Contact us, and we’ll get back to you within 3 business days.